However, only a few studies have evaluated the effect of TKI treatment before and after allo‐HCT, measurable residual disease (MRD) status, and additional cytogenetic abnormalities influencing transplant outcomes in patients with AML with BCR::ABL1. Here, BCR is linked to acute myeloid leukemia.